meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-CTLA-4
tremelimumab
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus pemetrexed plus platin
pembrolizumab based treatment
pembrolizumab alone
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
Immunostimulant
vaccine
UV1 vaccine
UV1 vaccine plus nivolumab and ipilimumab
no study with result for this clinical condition